[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 33 of about 33
1. Thomas DA, O'Brien S, Cortes J, Giles FJ, Faderl S, Verstovsek S, Ferrajoli A, Koller C, Beran M, Pierce S, Ha CS, Cabanillas F, Keating MJ, Kantarjian H: Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma. Blood; 2004 Sep 15;104(6):1624-30
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma.
  • Therapy of lymphoblastic lymphoma (LL) has evolved with use of chemotherapy regimens modeled after those for acute lymphocytic leukemia (ALL).
  • We treated 33 patients with LL with the intensive chemotherapy regimens hyper-CVAD (fractionated cyclophosphamide, vincristine, Adriamycin, and dexamethasone) or modified hyper-CVAD used for ALL at our institution.
  • Induction consolidation was administered with 8 or 9 alternating cycles of chemotherapy over 5 to 6 months with intrathecal chemotherapy prophylaxis, followed by maintenance therapy.
  • Consolidative radiation therapy was given to patients with mediastinal disease at presentation.
  • No parameters (eg, age, stage, serum lactate dehydrogenase [LDH], beta(2) microglobulin) appeared to influence outcome except for CNS disease at presentation.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclophosphamide / therapeutic use. Dexamethasone / therapeutic use. Doxorubicin / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Vincristine / therapeutic use
  • [MeSH-minor] Adolescent. Adult. Female. Humans. Male. Middle Aged. Prognosis. Salvage Therapy. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15178574.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; CVAD protocol
  •  go-up   go-down


2. Hoelzer D, Gökbuget N, Digel W, Faak T, Kneba M, Reutzel R, Romejko-Jarosinska J, Zwolinski J, Walewski J: Outcome of adult patients with T-lymphoblastic lymphoma treated according to protocols for acute lymphoblastic leukemia. Blood; 2002 Jun 15;99(12):4379-85
Genetic Alliance. consumer health - Lymphoblastic lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of adult patients with T-lymphoblastic lymphoma treated according to protocols for acute lymphoblastic leukemia.
  • We treated 45 adult patients with T-lymphoblastic lymphoma (T-LBL) (age range 15-61 years) with 2 protocols designed for adult acute lymphoblastic leukemia (ALL).
  • In our study, an 8-drug standard induction was administered over 8 weeks including prophylactic cranial (24 Gy) and mediastinal irradiation (24 Gy) followed by consolidation and reinduction therapy.
  • At diagnosis, 91% of the 45 patients showed a mediastinal tumor and 40% had pleural/pericardial effusions; 73% of the patients had stage III/IV disease.
  • In patients with stage I-III disease (n = 18) the CR rate was 100% compared with 89% in stage IV (n = 27).
  • The majority of relapses (47%) occurred in the mediastinum (n = 7) despite mediastinal irradiation with 24 Gy in 6 out of 7 patients.
  • Stage, age, lactate dehydrogenase, and all other parameters had no influence on achievement of CR or outcome.
  • This study demonstrates in a large cohort of patients with adult T-LBL that a high CR rate and a favorable outcome can be achieved with an ALL-type regimen.
  • Mediastinal recurrence was the major obstacle and further improvement by intensification of chemotherapy, increased dose of mediastinal irradiation (36 Gy), and extended indications for stem cell transplantation seem to be required.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Cranial Irradiation. Female. Humans. Male. Mediastinal Neoplasms / mortality. Mediastinal Neoplasms / radiotherapy. Mediastinal Neoplasms / therapy. Middle Aged. Pleural Neoplasms / mortality. Pleural Neoplasms / radiotherapy. Pleural Neoplasms / therapy. Radiation Dosage. Radiotherapy, Adjuvant. Recurrence. Remission Induction / methods. Risk Factors. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12036865.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


3. Fløisand Y, Brinch L, Dybedal I, Gedde-Dahl T, Heldal D, Holme PA, Egeland T, Tjønnfjord GE: [Allogeneic stem cell transplantation in adults with acute lymphoblastic leukaemia]. Tidsskr Nor Laegeforen; 2008 Nov 20;128(22):2563-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Allogeneic stem cell transplantation in adults with acute lymphoblastic leukaemia].
  • BACKGROUND: The success rate for chemotherapy of adults with acute lymphoblastic leukaemia in Norway compares favourably with that in international reports, but improvements are still needed.
  • MATERIAL AND METHODS: Allogen stem cell transplantation was performed in 61 high-risk patients (38 men and 23 women) with acute lymphoblastic leukaemia at Rikshospitalet between 1985 and 2005.
  • 19 patients were transplanted in first remission and 42 at a later stage of the disease.
  • Median survival time was 1.5 years.
  • Relapse was the most important cause of treatment failure (38%), but transplantation-related mortality (25%) was also a substantial problem.
  • INTERPRETATION: Our results are in line with international reports on the results of allogen stem cell transplantation in high-risk acute lymphoblastic leukaemia.
  • This treatment offers cure for patients with an otherwise dismal prognosis.
  • A larger number of patients should be offered such treatment during the first remission than what was the case in the 20-year period this study took place.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Adolescent. Adult. Disease-Free Survival. Female. Graft vs Host Disease / diagnosis. Graft vs Host Disease / prevention & control. Humans. Male. Middle Aged. Remission Induction. Risk Factors. Survival Analysis. Transplantation Conditioning. Transplantation, Homologous. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19023351.001).
  • [ISSN] 0807-7096
  • [Journal-full-title] Tidsskrift for den Norske lægeforening : tidsskrift for praktisk medicin, ny række
  • [ISO-abbreviation] Tidsskr. Nor. Laegeforen.
  • [Language] nor
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Norway
  •  go-up   go-down


Advertisement
4. Chen YC, Ho CL, Kao WY, Hwang JM, Sheu LF, Chao TY: Adult lymphoblastic lymphoma in Taiwan: an analysis of treatment results of 26 patients. Ann Hematol; 2001 Nov;80(11):647-52
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult lymphoblastic lymphoma in Taiwan: an analysis of treatment results of 26 patients.
  • Lymphoblastic lymphoma (LBL) frequently affects young adults and usually presents with a mediastinal mass as well as bone marrow involvement.
  • Although the frequency of LBL in the Far East is higher than that of Western countries, no reports regarding treatment of this disease have as yet been reported.
  • We herein report our treatment experience and verify the efficacy of the Stanford/Northern California Oncology Group (NCOG) protocol for this disease and recommend treatment strategies for LBL patients.
  • We retrospectively reviewed the medical records of adult LBL patients treated in our hospital from 1986 to 1996.
  • Nineteen patients had an initial stage IV disease.
  • Of the 23 cases in which immunological studies were performed, 20 proved to be of T cell lineage, 1 of B cell type, and the other 2 lacked both T and B markers.
  • One patient was excluded for analysis because of initial treatment by surgery.
  • Five patients with stage II-III diseases achieved long-term disease-free survival of 11-36 months with the Stanford/NCOG protocol with a median follow-up of 24 months.
  • Four patients in late stage or relapse received allogeneic bone marrow transplantation (BMT).
  • Two other patients in CR were treated with high-dose chemotherapy (HDCT) supported with autologous BMT and peripheral blood stem cell transplantation (PBSCT), respectively.
  • B symptoms and treatment without the Stanford/NCOG protocol were found to have significantly negative impacts on both patients' overall and progression-free survivals.
  • Our results suggest that the Stanford/NCOG protocol may be an effective chemotherapy for adult LBL and may provide long-term remission for patients in an early stage of disease.
  • For those patients with LBL in an advanced stage or in relapse, HDCT with allogeneic or autologous BMT is probably the treatment of choice.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Asparaginase / administration & dosage. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Prednisolone / administration & dosage. Vincristine / administration & dosage
  • [MeSH-minor] Adolescent. Adult. Aged. Bone Marrow Transplantation. Etoposide / administration & dosage. Female. Hematopoietic Stem Cell Transplantation. Humans. Male. Mechlorethamine / administration & dosage. Methotrexate / administration & dosage. Middle Aged. Prednisone / administration & dosage. Procarbazine / administration & dosage. Prognosis. Recurrence. Retrospective Studies. Survival Analysis. Taiwan. Treatment Outcome

  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. NITROGEN MUSTARD N-OXIDE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11757723.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 35S93Y190K / Procarbazine; 50D9XSG0VR / Mechlorethamine; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; EC 3.5.1.1 / Asparaginase; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate; CHOP protocol; ProMACE-MOPP protocol; Stanford-NCOG protocol
  •  go-up   go-down


5. Snyder DS: Allogeneic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia. Biol Blood Marrow Transplant; 2000;6(6):597-603
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Allogeneic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia.
  • The prognosis for adult and pediatric patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) treated with chemotherapy alone is extremely poor.
  • The experience with chemotherapy and autologous stem cell transplantation (SCT) is summarized.
  • Variables affecting outcome after allogeneic SCT, including age, stage of disease, source of stem cells, preparatory regimen, and molecular and cytogenetic details, are analyzed.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Adult. Child. Humans. Polymerase Chain Reaction. Survival Analysis. Transplantation, Homologous

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11128809.001).
  • [ISSN] 1083-8791
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P0 1 CA30206; United States / NCI NIH HHS / CA / P0 1 CA33572
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] United States
  • [Number-of-references] 51
  •  go-up   go-down


6. Lin P, Jones D, Dorfman DM, Medeiros LJ: Precursor B-cell lymphoblastic lymphoma: a predominantly extranodal tumor with low propensity for leukemic involvement. Am J Surg Pathol; 2000 Nov;24(11):1480-90
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Precursor B-cell lymphoblastic lymphoma: a predominantly extranodal tumor with low propensity for leukemic involvement.
  • Precursor B-cell lymphoblastic lymphoma (B-LBL) is uncommon and accounts for less than 10% of cases of lymphoblastic lymphoma.
  • Patients with concurrent precursor B-cell acute lymphoblastic leukemia (B-ALL) or a history thereof were excluded.
  • There was no evidence of bone marrow disease at the time of diagnosis in 23 patients; two patients had focal (<5%) involvement.
  • The treatment and survival data available for a subset of patients with B-LBL were compared with those from a series of patients with B-ALL at our institution.
  • The primary sites of disease were skin (nine cases), bones (five cases), soft tissue (four cases), lymph nodes, (three cases), breast (two cases), stomach and colon (one case), and mediastinum (one case).
  • Clinical stage was stage I in 13 cases, stage II in seven cases, stage III in three cases, and stage IV in two cases.
  • Of 14 patients with available survival data, all achieved complete clinical response after combination chemotherapy (13 patients) or surgical excision followed by local irradiation (one patient).
  • Five (35.7%) patients subsequently relapsed, including the patient who had received only irradiation, and four of these patients died after a median survival time of 60 months.
  • None of the patients had leukemia, although one patient developed extensive bone marrow involvement.
  • Unlike precursor T-cell lymphoblastic lymphoma, which commonly involves lymph nodes and the mediastinum, B-LBL usually involves extranodal sites, most often the skin, and rarely presents as a mediastinal mass.
  • With aggressive chemotherapy, patients with precursor B-LBL rarely develop leukemia and appear to have a better prognosis than do patients with B-ALL.
  • [MeSH-major] Lymphoma, B-Cell / pathology. Precancerous Conditions / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Antigens, Neoplasm / analysis. Biomarkers, Tumor / analysis. Bone Marrow / chemistry. Bone Marrow / pathology. Child. Child, Preschool. DNA, Neoplasm / analysis. Female. Flow Cytometry. Follow-Up Studies. Humans. Immunoenzyme Techniques. Immunophenotyping. In Situ Nick-End Labeling. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Staging. Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11075849.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm
  •  go-up   go-down


7. Jmili NB, Souguir S, Yacoub S, Khelif A, Kortas M: [Study of antigenic profile of blasts in acute lymphoblastic leukemia: flow cytometric analysis of 152 cases]. Ann Biol Clin (Paris); 2009 Sep-Oct;67(5):543-51
Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Study of antigenic profile of blasts in acute lymphoblastic leukemia: flow cytometric analysis of 152 cases].
  • [Transliterated title] Etude du profil antigénique des blastes au cours des leucémies aiguës lymphoblastiques : analyse de 152 cas par cytométrie en flux.
  • The aim of this study was to characterize the antigenic profile of blasts in acute lymphoblastic leukaemia (ALL) and to determine possible phenotypic aberrancies in a series of 152 patients with acute leukaemia diagnosed non myeloid leukaemia in cytology.
  • Based on criteria of EGIL (European Group of Immunological Leukaemia), cases were classified as: acute lymphoblastic leukaemia (ALL, 52,6%); 75% cases of ALL belong to lymphoid B lineage.
  • Flow cytometry has wide field of applications to characterize blast cells from patients with acute leukaemia: to establish diagnosis of lineage responsible in proliferation, to determine the stage of maturation, to predict prognosis for a better adaptation of adequate treatment, to follow evolution of disease after chemotherapy and to study minimal residual disease.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Female. Flow Cytometry. Humans. Immunophenotyping. Infant. Male. Middle Aged. Neprilysin / analysis. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19789126.001).
  • [ISSN] 0003-3898
  • [Journal-full-title] Annales de biologie clinique
  • [ISO-abbreviation] Ann. Biol. Clin. (Paris)
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


8. Jin FY, Zou DH, Wang GR, Xu Y, Feng SZ, Zhao YZ, Han MZ, Yan WW, Qiu LG: [Comparison of the effectiveness of chemotherapy and autologous hematopoietic stem cell transplantation as postremission treatment for adult acute lymphoblastic leukemia patients]. Zhonghua Xue Ye Xue Za Zhi; 2005 Nov;26(11):645-8
Genetic Alliance. consumer health - Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Comparison of the effectiveness of chemotherapy and autologous hematopoietic stem cell transplantation as postremission treatment for adult acute lymphoblastic leukemia patients].
  • OBJECTIVE: To evaluate the effectiveness of chemotherapy (CT) and autologous hematopoietic stem cell transplantation (ASCT) as post-remission treatment for adult acute lymphoblastic leukemia (AL) patients.
  • METHODS: Seventy-four ALL patients achieved first complete remission (CR(1)) with induction therapy, and then received early-stage sequential intensive consolidation chemotherapy.
  • After that, 40 patients received chemotherapy (CT group) and 34 received ASCT (ASCT group) as post-remission treatment.
  • (1) The median LFS and OS were 14.0 and 20.6 months respectively for CT group and both were more than 53.5 months for ASCT groups. (2) Relapse occurred in 28 patients (70%) in CT group in a median time of 8.5 months (range, 1-72 months) and 20 of them (71.43%) relapsed within 1 year.
  • Eleven patients (32.35%) relapsed in ASCT group, in a median time of 6 (2-30) months after transplantation. (3) There was no statistic difference in LFS, OS and relapse rate at 1 year between CT and ASCT groups (P > 0.05), whereas both LFS and OS at 3 and 5 years for ASCT group were significantly better than those for CT group (P < 0.05).
  • Relapse rate for ASCT group was lower than that for CT group. (4) Higher LFS and OS and lower relapse rate were found for those who received monoclonal antibody purged autografts followed by immunotherapy and (or) maintenance therapy after ASCT (P < 0.05).
  • CONCLUSIONS: Early sequential intensive consolidation chemotherapy followed by auto-HSCT could significantly reduce late relapse rate for adult ALL patients, and those received ex vivo purged autografts and immunotherapy and (or) maintenance therapy after ASCT have lower late relapse rate and superior survival.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hematopoietic Stem Cell Transplantation. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / surgery
  • [MeSH-minor] Adolescent. Adult. Female. Follow-Up Studies. Humans. Male. Retrospective Studies. Transplantation, Autologous. Treatment Outcome

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16620547.001).
  • [ISSN] 0253-2727
  • [Journal-full-title] Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  • [ISO-abbreviation] Zhonghua Xue Ye Xue Za Zhi
  • [Language] chi
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


9. Plasschaert SL, Kamps WA, Vellenga E, de Vries EG, de Bont ES: Prognosis in childhood and adult acute lymphoblastic leukaemia: a question of maturation? Cancer Treat Rev; 2004 Feb;30(1):37-51

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognosis in childhood and adult acute lymphoblastic leukaemia: a question of maturation?
  • Acute lymphoblastic leukaemia (ALL) is a disease diagnosed in children as well as adults.
  • Progress in the treatment of ALL has led to better survival rates, however, children have benefited more from improved treatment modalities than adults.
  • Recent evidence has underscored that the difference in characteristics and biology of adult versus childhood ALL might be the result of a different origin.
  • It has been suggested, that in childhood ALL the first genetic event happens in the more mature lymphoid committed progenitor cells, whereas in adult ALL the first hit occurs in multipotent stem cells.
  • This review compares patient characteristics, the extent of the disease, leukaemic cell characteristics and treatment between childhood and adult ALL.
  • This is discussed in relation to the hypothesis that the maturation stage of the cells, from which the leukaemia arises, is responsible for the differential behaviour of adult and childhood ALL.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / epidemiology
  • [MeSH-minor] Adolescent. Adult. Age Distribution. Biopsy, Needle. Child. Child, Preschool. Female. Humans. Immunohistochemistry. Male. Netherlands / epidemiology. Prevalence. Prognosis. Randomized Controlled Trials as Topic. Risk Factors. Sex Distribution. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14766125.001).
  • [ISSN] 0305-7372
  • [Journal-full-title] Cancer treatment reviews
  • [ISO-abbreviation] Cancer Treat. Rev.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Number-of-references] 152
  •  go-up   go-down


10. Specchia G, Pastore D, Carluccio P, Liso A, Mestice A, Rizzi R, Ciuffreda L, Pietrantuono G, Liso V: FLAG-IDA in the treatment of refractory/relapsed adult acute lymphoblastic leukemia. Ann Hematol; 2005 Nov;84(12):792-5
Hazardous Substances Data Bank. VIDARABINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FLAG-IDA in the treatment of refractory/relapsed adult acute lymphoblastic leukemia.
  • Relapsed or refractory adult acute lymphoblastic leukemias (ALL) have poor prognosis.
  • The strategy for treating these patients is through reinduction chemotherapy followed by allogeneic stem cell transplantation, provided that the toxicity of the salvage regimen is acceptable.
  • Twenty three patients with relapsed/refractory adult ALL were treated with fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin (FLAG-IDA).
  • Nine (39.1%) patients achieved complete remission (CR) following salvage therapy, whereas 13 (56.5%) patients were refractory, and one patient died in aplasia due to infection.
  • In patients achieving remission, the median time to reach absolute neutrophil count (ANC) more than 0.5x10(9)/l and 1x10(9)/l was 20 (range 16-25) and 24 (range 20-28) days from the start of chemotherapy, respectively.
  • Platelet levels of more than 20x10(9)/l and 100x10(9)/l were achieved in a median time of 23 (range 19-25) and 33 (range 28-39) days, respectively.
  • All nine patients who achieved CR received a second course with FLAG-IDA, and seven patients underwent allogeneic stem cell transplantation (four from a matched donor, one from a mismatched donor, and two from an unrelated donor), while two did not reach that stage due to early relapse from CR.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Stem Cell Transplantation
  • [MeSH-minor] Adult. Aged. Antibiotics, Antineoplastic / administration & dosage. Antibiotics, Antineoplastic / adverse effects. Cytarabine / administration & dosage. Cytarabine / adverse effects. Disease-Free Survival. Female. Granulocyte Colony-Stimulating Factor / administration & dosage. Granulocyte Colony-Stimulating Factor / adverse effects. Humans. Idarubicin / administration & dosage. Idarubicin / adverse effects. Leukocyte Count. Liver / injuries. Male. Middle Aged. Mucositis / etiology. Platelet Count. Recurrence. Remission Induction. Retrospective Studies. Salvage Therapy. Transplantation, Homologous. Treatment Outcome. Vidarabine / administration & dosage. Vidarabine / adverse effects. Vidarabine / analogs & derivatives

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. FLUDARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16047203.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 04079A1RDZ / Cytarabine; 143011-72-7 / Granulocyte Colony-Stimulating Factor; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine; ZRP63D75JW / Idarubicin
  •  go-up   go-down


11. Parovichnikova EN, Savchenko VG, Verniuk MA, Vinogradova OA, Misiurin AV, Vorob'ev IA, Domracheva EV, Tikhonova LIu, Rukavitsyn OA, Rossiev VA, Kliasova GA, Turkina AG, Liubimova LS, Mendeleeva LP, Isaev VG: [Acute lymphoblastic leukemias with aberrations of BCR-ABL genes]. Ter Arkh; 2005;77(7):11-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Acute lymphoblastic leukemias with aberrations of BCR-ABL genes].
  • AIM: To develop an original therapeutic strategy in Ph-positive acute lymphoblastic leukemia (ALL).
  • During the first stage of the study (November 2001-July 2004), 18 primary ALL patients were recruited in HRC, from July 2004 to January 2005--16 patients in HRC, N.N.
  • The diagnosis of Ph-positive ALL was established in detection of translocation t(9;22) by standard cytogenetic test or fluorescent hibridization in situ with double signal (D-FISH), or by polymerase chain reaction with reverse transcription (RT-PCR).
  • In detection of aberration of BCR-ABL gene the patients received stem hemopoietic cells, from June 2004 imatinib was added to chemotherapy in the period of induction and consolidation.
  • Achievement of molecular remission in BCR-ABL-positive ALL occurs also in standard chemotherapy but molecular remissions begin 2-4 months later than clinicohematological ones.
  • CONCLUSION: In using imatinib combination with chemotherapy, molecular remission can be achieved simultaneously with hematological one.
  • [MeSH-major] Fusion Proteins, bcr-abl / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Agents / therapeutic use. Benzamides. Female. Follow-Up Studies. Humans. Imatinib Mesylate. In Situ Hybridization, Fluorescence. Male. Middle Aged. Piperazines / therapeutic use. Pyrimidines / therapeutic use. Remission Induction. Retrospective Studies. Reverse Transcriptase Polymerase Chain Reaction. Treatment Outcome

  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16116902.001).
  • [ISSN] 0040-3660
  • [Journal-full-title] Terapevticheskiĭ arkhiv
  • [ISO-abbreviation] Ter. Arkh.
  • [Language] rus
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.2 / Fusion Proteins, bcr-abl
  •  go-up   go-down


12. Gökbuget N, Hoelzer D: Novel antibody-based therapy for acute lymphoblastic leukaemia. Best Pract Res Clin Haematol; 2006;19(4):701-13
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Novel antibody-based therapy for acute lymphoblastic leukaemia.
  • In recent decades rapid improvements in the results of treatment of adult acute lymphoblastic leukaemia (ALL) have been achieved.
  • This progress has been based mainly on intensification and optimization of chemotherapy, risk-adapted use of stem-cell transplantation, and improved supportive care.
  • However, results in adult patients are still considerably inferior to those in paediatric ALL, and a barrier to further intensification of chemotherapy appears to have been reached regarding toxicity.
  • More recently, the most significant progress has therefore been achieved by individualized and targeted therapy - for example, treatment with monoclonal antibodies (MoAbs).
  • In ALL, rituximab is combined with chemotherapy mainly in mature B-ALL and Burkitt's lymphoma, and interim results are very promising.
  • Recently studies with rituximab have also been initiated in B-precursor ALL.
  • Overall it can be stated that MoAb therapy in ALL is a promising treatment approach.
  • Monotherapy with MoAbs in relapsed ALL has also occasionally achieved responses, but greater effects can be expected from combination with chemotherapy and treatment in the state of minimal residual disease.
  • Details of these regimens - required level of antigen expression, timing, schedule, dosage and stage of disease - remain to be defined.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antigens, CD / drug effects. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16997178.001).
  • [ISSN] 1521-6926
  • [Journal-full-title] Best practice & research. Clinical haematology
  • [ISO-abbreviation] Best Pract Res Clin Haematol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, CD
  • [Number-of-references] 54
  •  go-up   go-down


13. Jabbour E, Koscielny S, Sebban C, Peslin N, Patte C, Gargi T, Biron P, Fermé C, Bourhis JH, Vantelon JM, Arnaud P, Ribrag V: High survival rate with the LMT-89 regimen in lymphoblastic lymphoma (LL), but not in T-cell acute lymphoblastic leukemia (T-ALL). Leukemia; 2006 May;20(5):814-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High survival rate with the LMT-89 regimen in lymphoblastic lymphoma (LL), but not in T-cell acute lymphoblastic leukemia (T-ALL).
  • The most appropriate treatment for lymphoblastic lymphomas (LL) remains uncertain.
  • Four patients had central nervous system involvement and 12 had bone marrow involvement and 24/27 (89%) had advanced Ann Arbor stage III-IV disease.
  • Complete remission (CR) was achieved in 20/27 patients, unconfirmed complete remission in three patients (residual mediastinal lesion on computed tomography scan) and four failed induction therapy (ORR: 85%).
  • The Ann Arbor stage, age and serum lactate dehydrogenase level did not influence outcomes.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia-Lymphoma, Adult T-Cell / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Bone Marrow / pathology. Disease Progression. Disease-Free Survival. Dose-Response Relationship, Drug. Female. Follow-Up Studies. Humans. Male. Middle Aged. Predictive Value of Tests. Prognosis. Remission Induction. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16511514.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article
  • [Publication-country] England
  •  go-up   go-down


14. Qin Y, Shi YK, He XH, Han XH, Zhou SY, Liu P, Yang JL, Yang S, Zhang CG, Dong M, Zhou LQ, Wang JW, Feng FY, Sun Y: [Comparison of the efficiency of CHOP-based regimen with or without high dose consolidation treatment combined with hematopoietic stem cell transplantation in 63 lymphoblastic lymphoma patients]. Zhonghua Zhong Liu Za Zhi; 2009 Jun;31(6):469-73
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Comparison of the efficiency of CHOP-based regimen with or without high dose consolidation treatment combined with hematopoietic stem cell transplantation in 63 lymphoblastic lymphoma patients].
  • OBJECTIVE: To retrospectively analyze and compare the treatment efficiency of CHOP-based regimens with or without high-dose consolidation treatment combined with hematopoietic stem cell transplantation (HDT-HSCT) in the patients with lymphoblastic lymphoma (LBL).
  • Forty-two of the 63 patients achieved complete response (CR), 26 of those subsequently received consolidation HDT-HSCT, while the other 16 had 6-8 cycles of standard CHOP-based treatment only.
  • RESULTS: Of the 63 patients, 57 had a T-LBL and 6 B-LBL, with a median age of 20 years, 19 (30.2%) had a stage I-II diseases and 44 (69.8%) stage III-IV diseases, 61.9% presented with a mediastinal mass.
  • Of the 42 patients who achieved CR, the 5-year OS rate of the patients who received HDT-HSCT as a consolidation therapy was 59.8% versus 14.6% of the patients treated by CHOP-based regimens alone (P=0.004).
  • Among the 18 patients with bone marrow involvement, 3 received allogeneic HSCT and were all still alive at the follow up time of 22, 32 and 37 months, respectively, while another 4 received auto-HSCT and all died of the disease within 14 months.
  • CONCLUSION: Short term treatment with a CHOP-based regimen is not sufficient for the patients with lymphoblastic lymphoma.
  • High-dose consolidation treatment and hematopoietic stem cell transplantation may improve overall survival and disease free survival.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Marrow / pathology. Hematopoietic Stem Cell Transplantation. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Cyclophosphamide / therapeutic use. Disease-Free Survival. Dose-Response Relationship, Drug. Doxorubicin / administration & dosage. Doxorubicin / therapeutic use. Female. Follow-Up Studies. Humans. Male. Middle Aged. Prednisone / administration & dosage. Prednisone / therapeutic use. Remission Induction. Retrospective Studies. Survival Rate. Vincristine / administration & dosage. Vincristine / therapeutic use. Young Adult

  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • Genetic Alliance. consumer health - Transplantation.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19950562.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


15. Zhang W, Fu R, Liu WH, Cheng YQ, Song WX, DU LJ, Ruan EB, Zhang LT, Wang XM, Liang Y, Wang GJ, Qu W, Song J, Zhang RL, Guan J, Li LJ, Zou P, Shao ZH: [Prognosis and related factors of acute lymphoblastic leukemia]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Oct;15(5):1102-6
Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prognosis and related factors of acute lymphoblastic leukemia].
  • In order to analyze the prognosis and related factors of acute lymphoblastic leukemia (ALL), 53 newly diagnosed ALL patients were enrolled in this study.
  • The therapeutic efficacy and prognosis of 53 cases of ALL were analyzed, the remission, relapse, overall survival and event-free survival were studied, and relation between different factors and prognosis of ALL were investigated by comparison of cases in same stage.
  • Median overall survival (OS) and median event-free survival (EFS) time were 4 and 1 months after remission respectively, OS and EFS rate of 18 month was 35.1% and 14.2%.
  • Absolute neutrophil count (ANC) at the end of the induction chemotherapy was an independent related factor of OS, the higher ANC, the lower risk of death.
  • The patients with or without chemotherapy related infection had different relapse rate.
  • The patients with bleeding after chemotherapy had lower OS when compared with those without bleeding.
  • It is concluded that there is higher relapse rate, poor prognosis in adult ALL in comparison with children.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17956700.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


16. McGrath P, Pitcher L: 'Enough is enough': qualitative findings on the impact of dexamethasone during reinduction/consolidation for paediatric acute lymphoblastic leukaemia. Support Care Cancer; 2002 Mar;10(2):146-55
Hazardous Substances Data Bank. DEXAMETHASONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 'Enough is enough': qualitative findings on the impact of dexamethasone during reinduction/consolidation for paediatric acute lymphoblastic leukaemia.
  • The results of a longitudinal study conducted with children undergoing treatment for acute lymphoblastic leukaemia (ALL) and their families in Brisbane, Australia, indicate that the emotional impact of one of the protocol drugs, dexamethasone, is acutely distressing.
  • The findings presented cover the second interviews with the parents and children of the first 11 ALL families to have completed the re-consolidation stage of treatment.
  • The results indicate that the negative impact of this drug is particularly severe during the reconsolidation stage, when families are exhausted with coping with the intensity of treatment.
  • The emotional consequences of the drug are profoundly disturbing, not only for the child, but for the whole family.
  • The findings indicate that the period when dexamethasone is being administered is an important time for providing families with emotional support and information about likely sequelae of treatment.
  • [MeSH-major] Antineoplastic Agents, Hormonal / therapeutic use. Dexamethasone / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / psychology
  • [MeSH-minor] Adaptation, Psychological. Adult. Australia / epidemiology. Child. Child Welfare / psychology. Child, Preschool. Family Health. Female. Humans. Infant. Infant Welfare / psychology. Life Change Events. Longitudinal Studies. Male. Middle Aged. Parents / psychology. Psychology. Remission Induction

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11862504.001).
  • [ISSN] 0941-4355
  • [Journal-full-title] Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
  • [ISO-abbreviation] Support Care Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 7S5I7G3JQL / Dexamethasone
  •  go-up   go-down


17. Soriano Guillén L, Muñoz Calvo MT, Pozo Román J, Contra Gómez T, Buño Soto M, Argente Oliver J: [Changes in gonadal function in post-pubertal male survivors of acute lymphoblastic leukemia and Hodgkin's disease]. An Esp Pediatr; 2000 Oct;53(4):318-23
Hazardous Substances Data Bank. MENOTROPINS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Changes in gonadal function in post-pubertal male survivors of acute lymphoblastic leukemia and Hodgkin's disease].
  • AIM: To study gonadal function in male patients surviving acute lymphoblastic leukemia (ALL) or Hodgkins disease (HD).
  • PATIENTS AND METHODS: Thirteen postpubertal males were studied (Tanner stage V), 9 with ALL and 4 with HD, who had received polychemotherapy during the pre-puberal period.
  • CONCLUSIONS: The chemotherapy protocols used in the treatment of HD and ALL produced a high incidence of germinal cell damage and subclinical alterations in the Leydig's cell function in males with HD.
  • Prepubertal state does not protect the testes from the harmful effects of chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Hodgkin Disease / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Testis / drug effects
  • [MeSH-minor] Adolescent. Adult. Case-Control Studies. Child. Cyclophosphamide / administration & dosage. Cyclophosphamide / adverse effects. Doxorubicin / administration & dosage. Doxorubicin / adverse effects. Follicle Stimulating Hormone / blood. Growth Hormone-Releasing Hormone / blood. Humans. Luteinizing Hormone / blood. Male. Mechlorethamine / administration & dosage. Mechlorethamine / adverse effects. Prednisone / administration & dosage. Prednisone / adverse effects. Procarbazine / administration & dosage. Procarbazine / adverse effects. Puberty. Sperm Count. Spermatozoa / drug effects. Survivors. Testosterone / blood. Vincristine / administration & dosage. Vincristine / adverse effects

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. NITROGEN MUSTARD N-OXIDE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. TESTOSTERONE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11083980.001).
  • [ISSN] 0302-4342
  • [Journal-full-title] Anales españoles de pediatría
  • [ISO-abbreviation] An. Esp. Pediatr.
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 35S93Y190K / Procarbazine; 3XMK78S47O / Testosterone; 50D9XSG0VR / Mechlorethamine; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9002-67-9 / Luteinizing Hormone; 9002-68-0 / Follicle Stimulating Hormone; 9034-39-3 / Growth Hormone-Releasing Hormone; VB0R961HZT / Prednisone; MOPP protocol; OPPA protocol
  •  go-up   go-down


18. Vang R, Medeiros LJ, Warnke RA, Higgins JP, Deavers MT: Ovarian non-Hodgkin's lymphoma: a clinicopathologic study of eight primary cases. Mod Pathol; 2001 Nov;14(11):1093-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian non-Hodgkin's lymphoma: a clinicopathologic study of eight primary cases.
  • Primary (localized) non-Hodgkin's lymphoma (NHL) of the ovary is rare.
  • All tumors were unilateral and Ann Arbor stage I(E).
  • Each tumor was classified according to the World Health Organization Classification as follows: diffuse large B-cell lymphoma (three cases), follicular lymphoma (two cases), Burkitt lymphoma (one case), T-cell anaplastic large cell lymphoma (one case), and precursor T-lymphoblastic lymphoma (one case).
  • Patients were treated by various combinations of surgery, chemotherapy, and radiotherapy.
  • With appropriate therapy, patients appear to have a favorable prognosis although follow-up is short for some patients in this study.
  • [MeSH-major] Lymphoma, Non-Hodgkin / pathology. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adult. Antigens, CD / analysis. Burkitt Lymphoma / metabolism. Burkitt Lymphoma / pathology. Cell Adhesion Molecules / analysis. DNA-Binding Proteins / analysis. Female. Humans. Immunohistochemistry. Lymphoma, B-Cell / metabolism. Lymphoma, B-Cell / pathology. Lymphoma, Follicular / metabolism. Lymphoma, Follicular / pathology. Lymphoma, Large B-Cell, Diffuse / metabolism. Lymphoma, Large B-Cell, Diffuse / pathology. Lymphoma, T-Cell / metabolism. Lymphoma, T-Cell / pathology. Middle Aged. Neprilysin / analysis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology. Proto-Oncogene Proteins / analysis. Proto-Oncogene Proteins c-bcl-2 / analysis. Proto-Oncogene Proteins c-bcl-6. Transcription Factors / analysis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11706069.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / CD99 protein, human; 0 / Cell Adhesion Molecules; 0 / DNA-Binding Proteins; 0 / Proto-Oncogene Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Proto-Oncogene Proteins c-bcl-6; 0 / Transcription Factors; EC 3.4.24.11 / Neprilysin
  • [Number-of-references] 37
  •  go-up   go-down


19. Diviné M, Casassus P, Koscielny S, Bosq J, Sebban C, Le Maignan C, Stamattoulas A, Dupriez B, Raphaël M, Pico JL, Ribrag V, GELA, GOELAMS: Burkitt lymphoma in adults: a prospective study of 72 patients treated with an adapted pediatric LMB protocol. Ann Oncol; 2005 Dec;16(12):1928-35
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Burkitt lymphoma in adults: a prospective study of 72 patients treated with an adapted pediatric LMB protocol.
  • BACKGROUND: We conducted a phase II study to evaluate in 72 adult patients the efficacy of the intensive LMB chemotherapy regimen, previously reported by the Société Française d'Oncologie Pédiatrique for children with Burkitt lymphoma and L3 acute lymphoblastic leukemia.
  • PATIENTS AND METHODS: Treatment began with a prephase (low-dose steroids, vincristine and cyclophosphamide), except in patients with low tumor burden.
  • Group A (resected stage I and abdominal stage II disease) received three courses of vincristine, cyclophosphamide, doxorubicin and prednisone.
  • Group B (not eligible for groups A or C) received five courses of chemotherapy comprising high-dose methotrexate, infusional cytarabine and intrathecal (IT) methotrexate.
  • CONCLUSION: Patients with advanced-stage Burkitt lymphoma, including those with bone marrow and/or central nervous system involvement, can be cured with a short-term intensive chemotherapy regime tailored to the tumor burden.

  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16284057.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; Q573I9DVLP / Leucovorin; VB0R961HZT / Prednisone; WI4X0X7BPJ / Hydrocortisone; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


20. Ozçelik T, Ozkalemkaş F, Kocaeli H, Altundal Y, Ener B, Ali R, Ozkocaman V, Hakyemez B, Tunali A: [Successful treatment of neuroaspergillosis in a patient with acute lymphoblastic leukemia: role of surgery, systemic antifungal therapy and intracavitary therapy]. Mikrobiyol Bul; 2009 Jul;43(3):499-506
Hazardous Substances Data Bank. CASPOFUNGIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Successful treatment of neuroaspergillosis in a patient with acute lymphoblastic leukemia: role of surgery, systemic antifungal therapy and intracavitary therapy].
  • Cerebral aspergillosis is a rare condition that generally exhibits a poor response to conventional antifungal drugs.
  • We report here a case of cerebral aspergillosis in a 34-years-old man with acute lymphoblastic leukaemia who was successfully treated with a combination of aggressive neurosurgery, intracavitary instillation of amphotericin B and voriconazole.
  • We aimed to emphazise the roles of surgery, intracavitary therapy and antifungal therapy in the management of neuroaspergillosis.
  • Under amphotericin-B therapy, the patient developed dysarthria and paralysis of the right side of his body.
  • The therapy was switched to voriconazole and caspofungin combination.
  • Due to disease progression during combination therapy, the patient had a second surgical resection resulting in a 75% reduction in lesion size.
  • Following surgical intervention, intracavitary instillation of amphotericin B (0.3 mg/day for 15 days) was performed alongside with combination therapy (voriconazole and caspofungin).
  • The patient died during his treatment course because of neutropenic typhilitis occurring in the aplastic phase.
  • It is stated that in patients with neuroaspergillosis radical neurosurgery leads to better outcomes if performed at an earlier stage.
  • Antifungal treatment of cerebral aspergillosis requires that the drug must cross the blood brain barrier.
  • The therapy should be prolonged beyond the resolution of all lesions and until reversal of the underlying predisposition.
  • We conclude that the use of neurosurgery and voriconazole together appears to be a reliable and effective treatment modality in patients with cerebral aspergillosis.
  • [MeSH-major] Antifungal Agents / therapeutic use. Aspergillus flavus / isolation & purification. Neuroaspergillosis / drug therapy. Neuroaspergillosis / surgery. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications
  • [MeSH-minor] Adult. Amphotericin B / administration & dosage. Amphotericin B / therapeutic use. Chemotherapy, Adjuvant. Drug Therapy, Combination. Echinocandins / administration & dosage. Echinocandins / therapeutic use. Fatal Outcome. Humans. Injections, Intraventricular. Male. Pyrimidines / administration & dosage. Pyrimidines / therapeutic use. Triazoles / administration & dosage. Triazoles / therapeutic use. Voriconazole

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Hazardous Substances Data Bank. AMPHOTERICIN B .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19795628.001).
  • [ISSN] 0374-9096
  • [Journal-full-title] Mikrobiyoloji bülteni
  • [ISO-abbreviation] Mikrobiyol Bul
  • [Language] tur
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Turkey
  • [Chemical-registry-number] 0 / Antifungal Agents; 0 / Echinocandins; 0 / Pyrimidines; 0 / Triazoles; 7XU7A7DROE / Amphotericin B; F0XDI6ZL63 / caspofungin; JFU09I87TR / Voriconazole
  •  go-up   go-down


21. Ho CL, Chen CY, Chen YC, Chao TY: Cerebral dural sinus thrombosis in acute lymphoblastic leukemia with early diagnosis by fast fluid-attenuated inversion recovery (FLAIR) MR image: a case report and review of the literature. Ann Hematol; 2000 Feb;79(2):90-4
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cerebral dural sinus thrombosis in acute lymphoblastic leukemia with early diagnosis by fast fluid-attenuated inversion recovery (FLAIR) MR image: a case report and review of the literature.
  • Cerebral dural sinus thrombosis (CDST) is a very rare complication of acute lymphoblastic leukemia (ALL) in adult patients.
  • A 23-year-old man with ALL developed dizziness, headache, diplopia, limb weakness, and a sensation of fullness in his head after his second induction chemotherapy with doxorubicin, prednisolone, and vincristine.
  • His symptoms were relieved soon after treatment with heparin.
  • MR imaging with FLAIR performed a second time 7 days later showed complete disappearance of the thrombosis.
  • The patient was treated continuously with oral anticoagulant therapy and the symptoms did not recur.
  • Anticoagulant therapy can be administered safely without precipitating the occurrence of infarction hemorrhage at such an early stage of CDST.
  • [MeSH-major] Magnetic Resonance Imaging / methods. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Sinus Thrombosis, Intracranial / diagnosis. Sinus Thrombosis, Intracranial / etiology
  • [MeSH-minor] Adolescent. Adult. Child. Female. Humans. Male

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Thrombosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10741922.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] GERMANY
  • [Number-of-references] 16
  •  go-up   go-down


22. Xia Y, Sun XF, Zhang CQ, Zhen ZJ, Wang ZH, Wang ZQ: [Primary study of relationship between serum level of VEGF and non-Hodgkin's lymphoma in children and adolescent patients]. Ai Zheng; 2004 Nov;23(11 Suppl):1448-50
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary study of relationship between serum level of VEGF and non-Hodgkin's lymphoma in children and adolescent patients].
  • This study was to investigate the serum level of VEGF in children and adolescent patients with non-Hodgkin's lymphoma (NHL).
  • METHODS: The serum levels of VEGF(sVEGF) in 24 pretreated NHL patients were detected by ELISA. sVEGF in 10 of the 24 patients who received complete response after treatment were also detected by ELISA.
  • The average serum VEGF level was 289.54 ng/L (35.11-826.8 ng/L) in 10 of The CR patients, 8 cases of them had a high VEGF level before treatment but a nearly normal level after first CR.
  • From the clinical data, a high serum level was not found associated with stage, gender, PS. score, IPI score, serum LDH and "B" symptoms et al.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / blood. Vascular Endothelial Growth Factor A / blood
  • [MeSH-minor] 6-Mercaptopurine / administration & dosage. Adolescent. Adult. Asparaginase / administration & dosage. Burkitt Lymphoma / blood. Burkitt Lymphoma / drug therapy. Child. Child, Preschool. Cyclophosphamide / administration & dosage. Cytarabine / administration & dosage. Daunorubicin / administration & dosage. Female. Humans. Lymphoma, Large B-Cell, Diffuse / blood. Lymphoma, Large B-Cell, Diffuse / drug therapy. Male. Methotrexate / administration & dosage. Precursor Cell Lymphoblastic Leukemia-Lymphoma / blood. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Prednisone / administration & dosage. Remission Induction. Vincristine / administration & dosage

  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. MERCAPTOPURINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15566654.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Vascular Endothelial Growth Factor A; 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 8N3DW7272P / Cyclophosphamide; E7WED276I5 / 6-Mercaptopurine; EC 3.5.1.1 / Asparaginase; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate; ZS7284E0ZP / Daunorubicin; AIEOP acute lymphoblastic leukemia protocol
  •  go-up   go-down


23. Wilder RB, Tucker SL, Ha CS, Rodriguez MA, Hess MA, Cabanillas FF, Cox JD: Dose-response analysis for radiotherapy delivered to patients with intermediate-grade and large-cell immunoblastic lymphomas that have completely responded to CHOP-based induction chemotherapy. Int J Radiat Oncol Biol Phys; 2001 Jan 1;49(1):17-22
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dose-response analysis for radiotherapy delivered to patients with intermediate-grade and large-cell immunoblastic lymphomas that have completely responded to CHOP-based induction chemotherapy.
  • PURPOSE: To test the hypothesis that prechemotherapy tumor size affects the dose of radiation that should be delivered to intermediate-grade and large-cell immunoblastic lymphomas that have completely responded to cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP)-based induction chemotherapy.
  • METHODS AND MATERIALS: From September 1988 through December 1996, 294 patients with newly diagnosed, Stage I-IV, intermediate-grade or large-cell immunoblastic lymphomas were enrolled on 2 prospective protocols at the M. D.
  • Treatment consisted of CHOP-based chemotherapy with or without involved field radiotherapy.
  • One hundred seventy-two patients, with 178 nodal sites and 87 nonbony, extranodal sites of disease achieved a complete response to 2-6 cycles of chemotherapy and underwent involved field radiotherapy.
  • Total radiation doses ranged from 30.0 to 50.4 Gy (mean +/- standard deviation: 39.7 +/- 2.5 Gy) over 22-49 days using a daily fraction size of 1.3-2.3 Gy.
  • Because various fraction sizes were delivered, the linear-quadratic model was used to convert total radiation doses to biologically equivalent doses given at 1.8 Gy per fraction (D1.8).
  • An alpha/beta ratio of 10 Gy was used for the lymphomas, resulting in D1.8 ranging from 29.1 to 50.8 Gy.
  • Regression tree analysis was also performed on patients with nonbony disease who received D1.8 = 29.1-39.1 Gy to determine if small lymphomas could be locally controlled with relatively low doses of radiation.
  • Regression tree analysis of nodal sites identified 3 distinct groups: (a) lymphomas < or = 10 cm and D1.8 = 29.1-39.1 Gy;.
  • (b) lymphomas < or = 10 cm and D1.8 = 39.2-50.8 Gy; and (c) lymphomas > 10 cm.
  • For nonbony lymphomas that measured < 3.5 cm, low doses of radiation resulted in excellent local control (5-year rates: 96% vs. 97% for D1.8 = 29.1-39.1 Gy vs. D1.8 = 39.2-50.8 Gy; p = 0.610).
  • For 3.5-10.0 cm lymphomas, higher doses of radiation resulted in better local control (5-year rates: 40% versus 98% for D1.8 = 29.1-39.1 Gy versus D1.8 = 39.2-50.8 Gy, p < 0.0001).
  • A narrow dose range (D1.8 = 39.2-40.7 Gy) was delivered to the 8 lymphomas measuring > 10 cm that completely responded to 6 cycles of chemotherapy, resulting in a 5-year local control rate of only 70%.
  • CONCLUSION: D1.8 ranging from 29.1 to 39.1 Gy yielded excellent local control for nonbony lymphomas measuring < 3.5 cm that had completely responded to a median of 3 cycles of CHOP-based chemotherapy.
  • D1.8 ranging from 39.2 to 50.8 Gy yielded excellent local control for nonbony lymphomas measuring 3.5-10.0 cm that completely responded to either 3 or 6 cycles of chemotherapy.
  • For nonbony lymphomas measuring > 10 cm that completely responded to 6 cycles of chemotherapy, D1.8 ranging from 39.2 to 40.7 Gy yielded suboptimal local control, suggesting that higher doses of radiation are indicated.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / radiotherapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Cyclophosphamide. Dose-Response Relationship, Radiation. Doxorubicin. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Prednisone. Prospective Studies. Radiotherapy Dosage. Regression Analysis. Vincristine

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11163493.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 6294
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


24. Chaidos A, Kanfer E, Apperley JF: Risk assessment in haemotopoietic stem cell transplantation: disease and disease stage. Best Pract Res Clin Haematol; 2007 Jun;20(2):125-54
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk assessment in haemotopoietic stem cell transplantation: disease and disease stage.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Neoplasms / therapy
  • [MeSH-minor] Acute Disease. Adult. Benzamides. Female. Humans. Imatinib Mesylate. Leukemia, Lymphocytic, Chronic, B-Cell / therapy. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy. Leukemia, Myeloid / therapy. Male. Multiple Myeloma / therapy. Myelodysplastic Syndromes / therapy. Neoplasm Staging. Piperazines / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Prognosis. Pyrimidines / therapeutic use. Recurrence. Risk Assessment. Survival Analysis. Transplantation, Homologous

  • Genetic Alliance. consumer health - Transplantation.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17448953.001).
  • [ISSN] 1521-6926
  • [Journal-full-title] Best practice & research. Clinical haematology
  • [ISO-abbreviation] Best Pract Res Clin Haematol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
  • [Number-of-references] 154
  •  go-up   go-down


25. Chauhan A, Weiss J, Warrier R: Effective management of pain in pediatric hematology and oncology. Asian Pac J Cancer Prev; 2010;11(2):577-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the last several decades, there have been major advances in the treatment of pediatric cancers.
  • 5 year survival of children with acute lymphoblastic leukemia has increased from 25% to 80%.
  • Bone pain is also a prominent symptom in late stage neuroblastoma, and of course in bone tumors.
  • Pain due to disease burden responds dramatically to chemotherapy and the uninitiated are often surprised by the sudden increase in activity and playfulness of children undergoing induction chemotherapy.
  • [MeSH-major] Hodgkin Disease / complications. Kidney Neoplasms / complications. Lymphoma, Non-Hodgkin / complications. Pain / drug therapy. Pain / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Wilms Tumor / complications
  • [MeSH-minor] Adult. Humans

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Pain.
  • MedlinePlus Health Information. consumer health - Wilms Tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20843157.001).
  • [ISSN] 2476-762X
  • [Journal-full-title] Asian Pacific journal of cancer prevention : APJCP
  • [ISO-abbreviation] Asian Pac. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down


26. Kaplan HG, Malmgren JA, Atwood M: Leukemia incidence following primary breast carcinoma treatment. Cancer; 2004 Oct 1;101(7):1529-36
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Leukemia incidence following primary breast carcinoma treatment.
  • BACKGROUND: The results of randomized clinical trials have suggested that after receiving radiotherapy and/or chemotherapy, patients with primary breast carcinoma have an increased risk of developing leukemia.
  • In the current study, the authors set out to assess the reported association between breast carcinoma treatment and leukemia risk.
  • Incidence rates were calculated for women who were treated for primary Stage 0-III breast carcinoma and had a follow-up duration of > or = 24 months (n = 2866).
  • Patients who did not undergo surgery (n = 5), patients for whom chemotherapy records were incomplete or who received nonstandard chemotherapy regimens (n = 69), patients who underwent stem cell transplantation (n = 83), and patients who were lost to follow-up or who had unknown disease status at follow-up (n = 81) were excluded from the analysis (total, n = 238).
  • Eight incident cases of leukemia were documented (2 cases of AML, 1 case of acute lymphoblastic leukemia, 1 case of MDS/refractory anemia with excess blasts, 2 cases of chronic myelogenous leukemia, and 2 cases of chronic lymphocytic leukemia).
  • The incidence of leukemia by treatment category was as follows: no surgery/no chemotherapy/no radiotherapy, 2 of 154 patients (1.30%); surgery/no chemotherapy/radiotherapy, 4 of 1403 patients (0.29%); surgery/chemotherapy/no radiotherapy, 0 of 352 patients (0%); and surgery/chemotherapy/radiotherapy, 2 of 957 patients (0.21%).
  • CONCLUSIONS: In contrast to findings reported from previous randomized clinical trials, the authors did not find evidence of increased posttreatment leukemia incidence in association with the use of chemotherapy, including doxorubicin-based regimens.
  • [MeSH-major] Breast Neoplasms / therapy. Leukemia / etiology. Neoplasms, Second Primary / etiology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / epidemiology. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / etiology. Leukemia, Myeloid, Acute / epidemiology. Leukemia, Myeloid, Acute / etiology. Middle Aged. Myelodysplastic Syndromes / epidemiology. Myelodysplastic Syndromes / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / epidemiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / etiology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2004 American Cancer Society.
  • [CommentIn] Cancer. 2004 Oct 1;101(7):1479-81 [15378475.001]
  • (PMID = 15378478.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


27. Hara S, Yokote T, Oka S, Akioka T, Kobayashi K, Hirata Y, Miyoshi T, Tsuji M, Hanafusa T: Endophthalmitis due to Trichosporon beigelii in acute leukemia. Int J Hematol; 2007 Jun;85(5):415-7
Hazardous Substances Data Bank. FLUCONAZOLE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We describe 2 patients with hematologic malignancy who developed endophthalmitis due to Trichosporon beigelii during the course of treatment with multiagent chemotherapy.
  • Although one of the patients was treated with fluconazole (FLCZ) and 5-fluorocytosine, the trichosporonous endophthalmitis was resistant to both drugs.
  • This patient subsequently received amphotericin B (AMPH-B) therapy, and the eyes were treated with vitrectomy.
  • In both patients, systemic treatment with AMPH-B successfully resolved the trichosporonous endophthalmitis that was resistant to multiple antifungal drugs.
  • The administration of AMPH-B is likely to be more effective in treating endophthalmitis due to trichosporonosis when the disease is at an early stage.
  • [MeSH-major] Endophthalmitis / complications. Endophthalmitis / microbiology. Leukemia, Myeloid / complications. Mycoses / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Trichosporon
  • [MeSH-minor] Acute Disease. Adult. Amphotericin B / administration & dosage. Antifungal Agents / administration & dosage. Drug Resistance, Fungal. Female. Fluconazole / administration & dosage. Flucytosine / administration & dosage. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Fungal Infections.
  • Hazardous Substances Data Bank. AMPHOTERICIN B .
  • Hazardous Substances Data Bank. FLUCYTOSINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Rocz Panstw Zakl Hig. 1994;45(4):337-46 [7792523.001]
  • [Cites] Medicine (Baltimore). 1986 Jul;65(4):268-79 [3523114.001]
  • [Cites] Cancer. 1975 Sep;36(3):1106-10 [52400.001]
  • [Cites] J Clin Oncol. 1991 Jul;9(7):1210-4 [2045861.001]
  • [Cites] Antimicrob Agents Chemother. 2000 Jan;44(1):57-62 [10602723.001]
  • [Cites] N Engl J Med. 1999 Mar 11;340(10):764-71 [10072411.001]
  • [Cites] Curr Top Med Mycol. 1993;5:79-113 [8242806.001]
  • [Cites] Ann Intern Med. 1985 Oct;103(4):620-5 [3862359.001]
  • [Cites] Antimicrob Agents Chemother. 2002 Jun;46(6):1857-69 [12019101.001]
  • [Cites] Ophthalmology. 1982 Feb;89(2):152-6 [6951137.001]
  • [Cites] Infect Dis Clin North Am. 1989 Mar;3(1):43-52 [2647833.001]
  • [Cites] Cancer. 1981 Nov 1;48(9):2107-11 [6945903.001]
  • [Cites] Retina. 2003 Jun;23(3):404-5 [12824845.001]
  • [Cites] Med Mycol. 2000 Feb;38(1):27-30 [10746224.001]
  • [Cites] Cancer. 1980 Jan 15;45(2):367-71 [6927961.001]
  • [Cites] Br J Ophthalmol. 1974 Jun;58(6):591-4 [4425639.001]
  • [Cites] Clin Infect Dis. 1992 Mar;14 Suppl 1:S161-9 [1314105.001]
  • [Cites] Clin Microbiol Infect. 2001;7 Suppl 2:8-24 [11525222.001]
  • [Cites] Rev Infect Dis. 1989 May-Jun;11(3):369-78 [2749101.001]
  • [Cites] Scand J Infect Dis. 1978;10(3):225-6 [715385.001]
  • [Cites] Am J Ophthalmol. 2005 Jan;139(1):135-40 [15652837.001]
  • [Cites] J Med Microbiol. 1970 Feb;3(1):191-3 [5448879.001]
  • [Cites] Blood. 2004 Sep 15;104(6):1624-30 [15178574.001]
  • [Cites] Chemotherapy. 1998 Jan-Feb;44(1):55-62 [9444410.001]
  • [Cites] Eur J Clin Chem Clin Biochem. 1997 Jul;35(7):553-60 [9263735.001]
  • [Cites] J Clin Lab Anal. 1995;9(5):334-9 [8531015.001]
  • [Cites] Clin Infect Dis. 1992 Nov;15(5):781-7 [1445976.001]
  • [Cites] Clin Infect Dis. 2003 Mar 1;36(5):630-7 [12594645.001]
  • [Cites] J Clin Microbiol. 1998 Oct;36(10 ):2950-6 [9738049.001]
  • [Cites] Mycoses. 1994 Jan-Feb;37(1-2):3-10 [7935589.001]
  • (PMID = 17562617.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antifungal Agents; 7XU7A7DROE / Amphotericin B; 8VZV102JFY / Fluconazole; D83282DT06 / Flucytosine
  •  go-up   go-down


28. Merkle M, Rupprecht HD: [Lymphoproliferative disease following kidney transplantation]. Dtsch Med Wochenschr; 2005 Jul 15;130(28-29):1691-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Bacterial or viral enteritis could be excluded as well as a mucosa-associated lymphatic tissue lymphoma (MALT-lymphoma).
  • Shortly thereafter, the patient developed a subileus.
  • Histology showed an EBV-negative, highly aggressive B-blastic lymphoma.
  • TREATMENT AND COURSE: Because of the advanced lymphoma stage immunosuppressive therapy was reduced and immunochemotherapy according to the CHOP-protocol (cyclophosphamide, doxorubicin, vincristine, prednisone) in combination with rituximab (R-CHOP) was started.
  • After 4 chemotherapy cycles the patient was in complete remission and another 2 therapy cycles were given for consolidation.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Kidney Transplantation / adverse effects. Lymphoma, B-Cell / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / etiology. Prednisone / therapeutic use. Vincristine / therapeutic use
  • [MeSH-minor] Abdominal Pain. Adult. Diagnosis, Differential. Diarrhea. Humans. Immunosuppressive Agents / administration & dosage. Immunosuppressive Agents / adverse effects. Male. Remission Induction. Risk Factors

  • Genetic Alliance. consumer health - Kidney Disease.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • MedlinePlus Health Information. consumer health - Steroids.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16003604.001).
  • [ISSN] 0012-0472
  • [Journal-full-title] Deutsche medizinische Wochenschrift (1946)
  • [ISO-abbreviation] Dtsch. Med. Wochenschr.
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


29. Kunsdorf-Wnuk A, Marzec-Lewenstein E, Arct-Danielak D, Musioł E, Bohatyrewicz R, Becht R: The use of recombinant human activated protein C (rhAPC) in the treatment of severe sepsis in immunosuppressed patients in the course of hematological diseases. Med Sci Monit; 2005 Aug;11(8):CS49-55
MedlinePlus Health Information. consumer health - Sepsis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The use of recombinant human activated protein C (rhAPC) in the treatment of severe sepsis in immunosuppressed patients in the course of hematological diseases.
  • BACKGROUND: Treatment of hemopoietic system neoplasias involves severe complications associated with immunosuppression.
  • We present two cases of treating severe sepsis utilizing recombinant human activated protein C (rhAPC) in the course of bilateral pneumonia in patients with hairy cell leukemia (HCL) and T-cell acute lymphoblastic leukemia (ALL).
  • CASE REPORT: Besides intensive, multidirectional treatment of severe sepsis, Xigris (activated drotrecogin alfa) was administered on the second day in both cases.
  • During treatment the patients' general condition and respiratory efficiency improved, allowing respirator weaning on days 5 and 8 of therapy.
  • These cases of severe sepsis and immunosuppression indicate a high therapeutic efficacy of drotrecogin alfa (activated).
  • Treatment outcome was uncertain because of the patients' hematological condition, so rapid restoration of respiratory efficiency and no disease progression after discontinuing treatment was a great success, possibly due to implementing Xigris at a relatively early stage of sepsis and the intensive therapy conducted according to Surviving Sepsis Campaign guidelines.
  • CONCLUSIONS: Patient survival in severe sepsis directly depends on early diagnosis and institution of treatment.
  • 1. These cases confirm the effectiveness of drotrecogin alfa in severe sepsis as part of multidirectional therapy.
  • [MeSH-major] Immune Tolerance. Leukemia, Hairy Cell / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Protein C / therapeutic use. Sepsis / complications. Sepsis / drug therapy
  • [MeSH-minor] Adult. Enzyme Activation. Humans. Male. Recombinant Proteins / therapeutic use

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16049385.001).
  • [ISSN] 1234-1010
  • [Journal-full-title] Medical science monitor : international medical journal of experimental and clinical research
  • [ISO-abbreviation] Med. Sci. Monit.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Protein C; 0 / Recombinant Proteins
  •  go-up   go-down


30. Ostrowska H, Hempel D, Holub M, Sokolowski J, Kloczko J: Assessment of circulating proteasome chymotrypsin-like activity in plasma of patients with acute and chronic leukemias. Clin Biochem; 2008 Nov;41(16-17):1377-83
Hazardous Substances Data Bank. CHYMOTRYPSIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: We evaluated whether the proteasomal chymotrypsin-like (ChT-L) activity is increased in plasma of patients with acute lymphoblastic (ALL), acute myeloblastic (AML) and chronic lymphocytic (CLL) leukemias.
  • RESULTS: The activity was significantly (P<0.001) higher in the plasma of ALL and AML patients at the diagnosis than in healthy subjects and decreased after therapy or remained unchanged or rose during relapse.
  • CONCLUSIONS: Plasma proteasome ChT-L activity can be a useful bio-marker for patients with acute leukemia at the blast stage.
  • [MeSH-minor] Adolescent. Adult. Aged. Case-Control Studies. Female. Humans. Hydrolysis / drug effects. L-Lactate Dehydrogenase / blood. Leukemia, Lymphocytic, Chronic, B-Cell / blood. Leukemia, Lymphocytic, Chronic, B-Cell / diagnosis. Leukemia, Myeloid, Acute / blood. Leukemia, Myeloid, Acute / diagnosis. Male. Middle Aged. Oligopeptides / pharmacology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / blood. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Proteasome Inhibitors. Protein Subunits / metabolism. Sodium Dodecyl Sulfate / pharmacology

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • Hazardous Substances Data Bank. SODIUM LAURYL SULFATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18773885.001).
  • [ISSN] 1873-2933
  • [Journal-full-title] Clinical biochemistry
  • [ISO-abbreviation] Clin. Biochem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Oligopeptides; 0 / Proteasome Inhibitors; 0 / Protein Subunits; 134381-21-8 / epoxomicin; 368GB5141J / Sodium Dodecyl Sulfate; EC 1.1.1.27 / L-Lactate Dehydrogenase; EC 3.4.21.1 / Chymotrypsin; EC 3.4.25.1 / Proteasome Endopeptidase Complex
  •  go-up   go-down


31. Styczynski J, Wysocki M, Debski R, Czyzewski K, Balwierz W, Juraszewska E, Matysiak M, Malinowska I, Stanczak E, Sońta-Jakimczyk D, Szczepanski T, Wachowiak J, Konatkowska B, Balcerska A, Ploszynska A, Kowalczyk J, Stefaniak J, Badowska W, Wieczorek M, Olejnik I, Krawczuk-Rybak M, Kuzmicz M: In vitro sensitivity of leukemic cells to nucleoside derivatives in childhood acute leukemias: good activity in leukemic relapses. Neoplasma; 2005;52(1):74-8
Hazardous Substances Data Bank. VIDARABINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Nucleoside analogues such as fludarabine and cladribine are used in therapy of indolent lymphomas and leukemias in adults, while cytarabine is used mainly in protocols for acute leukemias.
  • The objective of the study was the analysis of in vitro cellular drug sensitivity in childhood acute lymphoblastic (ALL) and myeloid (AML) leukemia.
  • Drug concentration lethal to 50% of tested cells was regarded as a value of drug resistance.
  • Unexpectedly, no differences were observed between initial and relapsed AML samples for all tested drugs, what suggests that nucleoside analogues are active drugs in relapsed AML, which is commonly regarded as a resistant disease.
  • All tested drugs presented significant cross-resistance in each of analyzed subgroups.
  • In summary, tested nucleoside analogues presented relatively good activity against childhood leukemias at relapse stage.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Cladribine / pharmacology. Cytarabine / pharmacology. Leukemia, Myeloid / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology. Vidarabine / analogs & derivatives. Vidarabine / pharmacology
  • [MeSH-minor] Adolescent. Adult. Cell Death. Child. Child, Preschool. Dose-Response Relationship, Drug. Drug Resistance, Neoplasm. Drug Screening Assays, Antitumor. Female. Humans. Infant. Infant, Newborn. Male. Recurrence. Tumor Cells, Cultured

  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. CLADRIBINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15739031.001).
  • [ISSN] 0028-2685
  • [Journal-full-title] Neoplasma
  • [ISO-abbreviation] Neoplasma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Slovakia
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 04079A1RDZ / Cytarabine; 47M74X9YT5 / Cladribine; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine
  •  go-up   go-down


32. Horowitz N, Brenner B: Thrombophilia and cancer. Pathophysiol Haemost Thromb; 2008;36(3-4):131-6
MedlinePlus Health Information. consumer health - Cancer in Children.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Most studies are small, and results are varied by geography, tumor type, stage of disease and therapy.
  • [MeSH-minor] Activated Protein C Resistance / complications. Activated Protein C Resistance / genetics. Adult. Antibodies, Antiphospholipid / blood. Antineoplastic Agents / adverse effects. Antineoplastic Agents / therapeutic use. Antineoplastic Agents, Hormonal / adverse effects. Antineoplastic Agents, Hormonal / therapeutic use. Asparaginase / adverse effects. Asparaginase / therapeutic use. Catheterization, Central Venous / adverse effects. Child. Factor V / genetics. Female. Genotype. Humans. Hyperhomocysteinemia / blood. Hyperhomocysteinemia / complications. Male. Methylenetetrahydrofolate Reductase (NADPH2) / genetics. Middle Aged. Precursor Cell Lymphoblastic Leukemia-Lymphoma / blood. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Prothrombin / genetics. Risk Factors. Thrombosis / etiology. Thrombosis / physiopathology. Thrombosis / prevention & control

  • Genetic Alliance. consumer health - Thrombophilia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 S. Karger AG, Basel.
  • (PMID = 19176986.001).
  • [ISSN] 1424-8840
  • [Journal-full-title] Pathophysiology of haemostasis and thrombosis
  • [ISO-abbreviation] Pathophysiol. Haemost. Thromb.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antibodies, Antiphospholipid; 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Hormonal; 0 / factor V Leiden; 9001-24-5 / Factor V; 9001-26-7 / Prothrombin; EC 1.5.1.20 / Methylenetetrahydrofolate Reductase (NADPH2); EC 3.5.1.1 / Asparaginase
  • [Number-of-references] 38
  •  go-up   go-down


33. Holowiecka-Goral A, Hołowiecki J, Giebel S, Stella-Holowiecka B, Krawczyk-Kulis M, Kos K, Lehmann-Kopydłowska A, Dudzinski M, Hałasz M, Preisner W, Cioch M, Piszcz J: Liposomal cytarabine in advanced-stage acute lymphoblastic leukemia and aggressive lymphoma with central nervous system involvement: experience of the Polish Acute Leukemia Group. Leuk Lymphoma; 2009 Mar;50(3):478-80
Hazardous Substances Data Bank. CYTARABINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liposomal cytarabine in advanced-stage acute lymphoblastic leukemia and aggressive lymphoma with central nervous system involvement: experience of the Polish Acute Leukemia Group.
  • [MeSH-major] Central Nervous System Neoplasms / drug therapy. Cytarabine / administration & dosage. Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Drug Carriers. Female. Humans. Liposomes. Male. Middle Aged. Poland. Remission Induction. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19294561.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Drug Carriers; 0 / Liposomes; 04079A1RDZ / Cytarabine
  •  go-up   go-down






Advertisement